We can finally tell which tiny glitches in your blood are totally harmless and which ones are ticking time bombs for a heart attack or cancer.
April 6, 2026
Original Paper
Mutation-specific impairment of TET2 and DNMT3A enzymatic activity predicts clonal hematopoiesis disease risk
medRxiv · 10.64898/2026.04.03.26350108
AI-generated illustration
The Takeaway
By studying over a million people, researchers found that the specific level of enzyme disruption caused by a mutation determines a person's actual health risk. This allows doctors to use a blood test to distinguish between benign genetic changes and those that require urgent medical attention.
From the abstract
Clonal hematopoiesis of indeterminate potential (CHIP) driven by somatic mutations in TET2 and DNMT3A is present in >10% of adults over 60 and confers substantial risk for hematologic malignancy and cardiovascular disease, yet the majority of patients with CHIP do not progress to disease. Analyzing 1,020,538 individuals across three biobanks (UK Biobank, All of Us, BioVU), we show that a discrete subset of enzymatically disruptive mutations, TET2 loss-of-function variants and the DNMT3A R882 hot